Scienture (SCNX)
Market Price (3/30/2026): $0.443 | Market Cap: $8.4 MilSector: Consumer Staples | Industry: Drug Retail
Scienture (SCNX)
Market Price (3/30/2026): $0.443Market Cap: $8.4 MilSector: Consumer StaplesIndustry: Drug Retail
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 208% | Weak multi-year price returns2Y Excs Rtn is -119%, 3Y Excs Rtn is -150% | Penny stockMkt Price is 0.4 |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -87% | Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 16% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -17 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2648% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 12x | ||
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1701%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1701% | ||
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -262% | ||
| High stock price volatilityVol 12M is 373% | ||
| Key risksSCNX key risks include [1] severe financial distress with a high potential for bankruptcy and [2] uncertainty surrounding the regulatory approval and commercial success of its key drug pipeline. |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 208% |
| Valuation becoming less expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is -87% |
| Weak multi-year price returns2Y Excs Rtn is -119%, 3Y Excs Rtn is -150% |
| Meaningful short interestShort Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 16% |
| Penny stockMkt Price is 0.4 |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -17 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -2648% |
| Expensive valuation multiplesP/SPrice/Sales ratio is 12x |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -1701%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -1701% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -262% |
| High stock price volatilityVol 12M is 373% |
| Key risksSCNX key risks include [1] severe financial distress with a high potential for bankruptcy and [2] uncertainty surrounding the regulatory approval and commercial success of its key drug pipeline. |
Qualitative Assessment
AI Analysis | Feedback
Scienture (SCNX) stock has lost about 30% since 11/30/2025 because of the following key factors:
1. Continued Financial Losses and Negative Operational Metrics. Scienture Holdings (SCNX) reported an Earnings Per Share (EPS) of -$0.19 for Q3 2025, missing analyst estimates of $0.00. As of October 2025, the company exhibited significantly negative profitability, with EBIT and EBITDA margins at -15614.4% and -14074.5%, respectively. These figures underscore ongoing operational inefficiencies and a persistent accumulated deficit of $42,102,970 as of March 31, 2025. The company also reported a significant cash flow deficit, including a decline of over $2 million in operating cash flow for Q2 2025, and a precarious current ratio of 0.1, raising concerns about its short-term financial obligations.
2. Share Dilution from Capital Raising Activities. Scienture secured $1.2 million in bridge funding through the issuance of common stock in July 2025, as part of a larger approved capital raise of up to $3 million. Furthermore, the company has indicated its use of At-The-Market (ATM) facilities to supplement its capital runway. While providing necessary capital, such common stock issuances and ATM offerings typically lead to the dilution of existing shareholder value by increasing the total number of outstanding shares.
Show more
1. Continued Financial Losses and Negative Operational Metrics. Scienture Holdings (SCNX) reported an Earnings Per Share (EPS) of -$0.19 for Q3 2025, missing analyst estimates of $0.00. As of October 2025, the company exhibited significantly negative profitability, with EBIT and EBITDA margins at -15614.4% and -14074.5%, respectively. These figures underscore ongoing operational inefficiencies and a persistent accumulated deficit of $42,102,970 as of March 31, 2025. The company also reported a significant cash flow deficit, including a decline of over $2 million in operating cash flow for Q2 2025, and a precarious current ratio of 0.1, raising concerns about its short-term financial obligations.
2. Share Dilution from Capital Raising Activities. Scienture secured $1.2 million in bridge funding through the issuance of common stock in July 2025, as part of a larger approved capital raise of up to $3 million. Furthermore, the company has indicated its use of At-The-Market (ATM) facilities to supplement its capital runway. While providing necessary capital, such common stock issuances and ATM offerings typically lead to the dilution of existing shareholder value by increasing the total number of outstanding shares.
Show more
Stock Movement Drivers
Fundamental Drivers
The -30.4% change in SCNX stock from 11/30/2025 to 3/29/2026 was primarily driven by a -30.4% change in the company's P/S Multiple.| (LTM values as of) | 11302025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.60 | 0.42 | -30.4% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 1 | 0.0% |
| P/S Multiple | 17.4 | 12.1 | -30.4% |
| Shares Outstanding (Mil) | 19 | 19 | 0.0% |
| Cumulative Contribution | -30.4% |
Market Drivers
11/30/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| SCNX | -30.4% | |
| Market (SPY) | -5.3% | 23.5% |
| Sector (XLP) | 3.9% | -20.7% |
Fundamental Drivers
The -57.2% change in SCNX stock from 8/31/2025 to 3/29/2026 was primarily driven by a -88.8% change in the company's P/S Multiple.| (LTM values as of) | 8312025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.97 | 0.42 | -57.2% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 1 | 409.7% |
| P/S Multiple | 107.5 | 12.1 | -88.8% |
| Shares Outstanding (Mil) | 14 | 19 | -25.4% |
| Cumulative Contribution | -57.2% |
Market Drivers
8/31/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| SCNX | -57.2% | |
| Market (SPY) | 0.6% | 8.2% |
| Sector (XLP) | 2.8% | -6.0% |
Fundamental Drivers
The -84.3% change in SCNX stock from 2/28/2025 to 3/29/2026 was primarily driven by a -87.5% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282025 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.65 | 0.42 | -84.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 0 | 1 | 207.9% |
| P/S Multiple | 29.6 | 12.1 | -59.2% |
| Shares Outstanding (Mil) | 2 | 19 | -87.5% |
| Cumulative Contribution | -84.3% |
Market Drivers
2/28/2025 to 3/29/2026| Return | Correlation | |
|---|---|---|
| SCNX | -84.3% | |
| Market (SPY) | 9.8% | 9.1% |
| Sector (XLP) | 1.1% | 0.9% |
Fundamental Drivers
The -89.3% change in SCNX stock from 2/28/2023 to 3/29/2026 was primarily driven by a -97.1% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 2282023 | 3292026 | Change |
|---|---|---|---|
| Stock Price ($) | 3.89 | 0.42 | -89.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 11 | 1 | -94.0% |
| P/S Multiple | 0.2 | 12.1 | 6095.1% |
| Shares Outstanding (Mil) | 1 | 19 | -97.1% |
| Cumulative Contribution | -89.3% |
Market Drivers
2/28/2023 to 3/29/2026| Return | Correlation | |
|---|---|---|
| SCNX | -89.3% | |
| Market (SPY) | 69.4% | 6.7% |
| Sector (XLP) | 23.1% | 3.4% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| SCNX Return | -55% | -83% | -14% | 87% | -92% | -11% | -99% |
| Peers Return | 36% | 21% | 2% | 8% | 26% | 4% | 137% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | -5% | 72% |
Monthly Win Rates [3] | |||||||
| SCNX Win Rate | 42% | 25% | 42% | 33% | 17% | 33% | |
| Peers Win Rate | 62% | 62% | 43% | 47% | 60% | 53% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 33% | |
Max Drawdowns [4] | |||||||
| SCNX Max Drawdown | -55% | -88% | -35% | -21% | -92% | -27% | |
| Peers Max Drawdown | -6% | -11% | -20% | -6% | -13% | -5% | |
| S&P 500 Max Drawdown | -1% | -25% | -1% | -2% | -15% | -5% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: JNJ, PFE, ABBV, LLY, MRK.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 3/27/2026 (YTD)
How Low Can It Go
| Event | SCNX | S&P 500 |
|---|---|---|
| 2022 Inflation Shock | ||
| % Loss | -96.7% | -25.4% |
| % Gain to Breakeven | 2918.1% | 34.1% |
| Time to Breakeven | Not Fully Recovered days | 464 days |
| 2020 Covid Pandemic | ||
| % Loss | -58.6% | -33.9% |
| % Gain to Breakeven | 141.5% | 51.3% |
| Time to Breakeven | Not Fully Recovered days | 148 days |
| 2018 Correction | ||
| % Loss | -76.0% | -19.8% |
| % Gain to Breakeven | 316.7% | 24.7% |
| Time to Breakeven | 252 days | 120 days |
Compare to JNJ, PFE, ABBV, LLY, MRK
In The Past
Scienture's stock fell -96.7% during the 2022 Inflation Shock from a high on 2/9/2021. A -96.7% loss requires a 2918.1% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Scienture (SCNX)
SCIENTURE HOLDINGS, Inc is a comprehensive health services and pharmaceutical product company focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs, optimize the prescription journey and patient engagement in the U.S.
AI Analysis | Feedback
Here are 1-3 brief analogies for Scienture (SCNX):
- Like a specialty pharmaceutical company such as Vertex Pharmaceuticals, but with an integrated layer of patient services to optimize the entire prescription journey.
- Imagine Gilead Sciences for targeted specialty drugs, but offering more robust patient engagement and navigation support.
- It's like Moderna creating innovative therapies for niche health needs, combined with dedicated support to guide patients through their treatment access and adherence.
AI Analysis | Feedback
- Specialty Pharmaceutical Products: Scienture acquires, develops, and distributes novel specialty medications addressing unmet market needs for patients and caregivers.
- Patient Engagement and Support Services: The company provides services to optimize the patient prescription journey, including adherence programs, financial assistance, and education to enhance patient outcomes.
- Specialty Pharmacy Fulfillment: Scienture offers comprehensive pharmacy services for the dispensing and delivery of complex specialty medications to patients.
AI Analysis | Feedback
Scienture Holdings, Inc. (SCNX) is a pharmaceutical product and health services company. Companies in the pharmaceutical sector typically distribute their products through a network of other businesses within the healthcare supply chain rather than selling directly to individual patients. Therefore, Scienture's major customers are primarily other companies.
Based on its business model as a pharmaceutical product company, Scienture's major customers are likely large pharmaceutical wholesalers and distributors, who then supply pharmacies, hospitals, and other healthcare providers across the U.S.
Major potential customers in this category include:
- McKesson Corporation (MCK)
- AmerisourceBergen Corporation (ABC)
- Cardinal Health, Inc. (CAH)
These companies are crucial intermediaries for pharmaceutical manufacturers, ensuring widespread distribution of products to the ultimate points of care.
AI Analysis | Feedback
nullAI Analysis | Feedback
Shankar Hariharan, Ph.D. Executive Chairman and Co-CEO
Dr. Shankar Hariharan is the Founder, President, and CEO of Scienture, Inc. prior to its merger with Scienture Holdings, Inc. in July 2024. He possesses over 35 years of experience in successfully leading branded, specialty, and generic pharmaceutical businesses, having held leadership positions at Forest Labs, Par Pharmaceuticals, and Amneal Pharmaceuticals. As Executive Vice President and Chief Scientific Officer at Amneal, he oversaw Global Research and Development, Global Regulatory Affairs, and Specialty Product Development, and was instrumental in achieving significant revenue growth. His career includes involvement with the development and launch of notable brand products such as Celexa®, Lexapro®, Namenda®, and Megace ES®. Dr. Hariharan currently serves on the Board of Depymed, Inc. and the Advisory Board of New Rhein Healthcare, LLC and MAA Laboratories.
Narasimhan Mani, Ph.D., MBA President and Co-CEO
Dr. Narasimhan Mani is an experienced healthcare professional with over 25 years of experience in the pharmaceutical industry. He previously served as President & CEO for Kesin Pharma Corporation, a specialty pharmaceutical company, and as CEO of Xiromed LLC, a generics and specialty drug product company. His past roles also include Vice President of Global Corporate Strategy and Business Development at Amneal Pharmaceuticals, where he led strategic initiatives across global strategy, portfolio management, business development, and commercial operations. Dr. Mani has been instrumental in the launches of products like Ritalin® and Namenda XR®.
Eric Sherb Chief Financial Officer
Eric Sherb was appointed Chief Financial Officer of Scienture Holdings, Inc. in March 2025. He had been a consultant for the company since 2023. Mr. Sherb brings over 16 years of experience in accounting and finance, including expertise in financial reporting for public companies. He controls EMS Consulting Services, Inc., with which Scienture Holdings entered into an agreement for his services.
Prashant Patel President & Chief Operating Officer, Scienture Holdings, Inc.
Prashant Patel, a registered pharmacist (R.Ph.), serves as the President & Chief Operating Officer of Scienture Holdings, Inc. Prior to Eric Sherb's appointment, he served as the interim CFO. His dual role highlights his comprehensive involvement in both the strategic leadership and the operational execution of the company.
Rahul Surana, Ph.D., MBA Executive Vice President & Chief Operating Officer, Scienture LLC
Dr. Rahul Surana is a seasoned business leader with over two decades of expertise in the healthcare and pharmaceutical industries, spanning corporate strategy, R&D, and business development. At Scienture, he has played a pivotal role in building a robust 505(b)(2) NDA portfolio for the U.S. market, focusing on cardiovascular and central nervous system diseases. He has been instrumental in managing operations, finance, IT, and human resources, and in raising funds through seed rounds, convertible notes, and licensing deals.
AI Analysis | Feedback
The key risks to Scienture (SCNX) are:
- Financial Distress and Going Concern Risk: Scienture is facing significant financial challenges, including substantial operating losses, negative cash flow, and a working capital deficit. The company's Altman Z-Score indicates financial distress and a potential risk of bankruptcy within the next two years. It has also a low cash balance and is dependent on its ability to raise future funding to continue its operations. Additionally, Scienture has received a Nasdaq notice for failing to meet the minimum bid price requirement.
- Commercial Execution Risk for New Products: Scienture has recently pivoted to a specialty pharmaceutical model with FDA-approved products, Arbli™ and REZENOPY®, scheduled for commercial launch. There is a significant risk associated with the successful execution of these product launches, including achieving market adoption, securing payer access and group purchasing agreements, and managing competition. The company's current high valuation is largely predicated on rapid sales growth from these products, and any failure to meet these commercial targets could lead to a substantial decrease in its share price.
- Shareholder Dilution Risk: To finance its operations and new product launches, Scienture has historically relied on various funding mechanisms, including equity offerings and equity line drawdowns. This practice has led to significant dilution for existing shareholders in the past, and the ongoing need for capital raises the likelihood of further dilution, which could negatively impact the stock price.
AI Analysis | Feedback
null
AI Analysis | Feedback
Scienture Holdings, Inc. (SCNX) operates as a comprehensive health services and pharmaceutical product company, focusing on novel specialty products within the U.S. market. The addressable markets for its main products and services are as follows:
- TRxADE Platform: This proprietary web-based platform facilitates trade among healthcare buyers and sellers of pharmaceuticals, accessories, and services for U.S. independent pharmacies. Scienture targets 24,000 U.S. independent pharmacies with combined annual pharmaceutical purchases of $93 billion. The broader U.S. pharmaceutical industry, which includes these transactions, is valued at $330 billion annually.
- ARBLI (losartan potassium Oral Suspension): ARBLI is the first FDA-approved ready-to-use oral liquid formulation of losartan in the U.S. market, indicated for the treatment of hypertension, reduction of stroke risk in specific patients, and diabetic nephropathy. The U.S. losartan market is approximately $245 million annually, with 71 million prescriptions.
- REZENOPY (naloxone HCl nasal spray): REZENOPY is a high-strength naloxone nasal spray approved by the FDA for the emergency treatment of opioid overdose. The U.S. naloxone market has annual sales of approximately $154 million and a unit volume of 9.3 million.
AI Analysis | Feedback
Scienture Holdings, Inc. (SCNX) is expected to drive future revenue growth over the next 2-3 years through several key initiatives within its health services and pharmaceutical product focus. Here are 4 expected drivers of future revenue growth for Scienture:- Commercialization and expanded market access of Arbli™: The company has reported significant commercial progress and expanded market access for Arbli™, its FDA-approved ready-to-use oral suspension of losartan potassium. The commencement of commercial sales for Arbli™ has been noted as a factor in the company's stock performance, indicating its potential as a revenue driver.
- Launch of new specialty pharmaceutical products, particularly REZENOPY™ naloxone nasal spray: Scienture has confirmed the upcoming launch of its high-strength REZENOPY™ naloxone nasal spray, expected in Q2 2026. The company has already secured multiple Group Purchasing Organization (GPO) deals for this product, which are crucial for market penetration and distribution.
- Advancement and potential commercialization of pipeline drug candidates: Scienture has a pipeline of product candidates, including SCN-102 for hypertension, SCN-104 for acute migraine headaches, SCN-106 as a thrombolytic agent, and SCN-107 for post-surgical analgesia. Successful progression through clinical development and eventual market approval of these novel specialty products designed to satisfy unmet market needs will contribute significantly to future revenue.
- Strategic partnerships to optimize prescription journey and patient engagement: Scienture is actively forming strategic partnerships, such as the collaboration with BlinkRx to expand access to liquid losartan. These partnerships are aligned with the company's focus on optimizing the prescription journey and patient engagement, which can lead to increased product adoption and broader market reach.
AI Analysis | Feedback
Share Issuance
- In August 2025, Scienture Holdings, Inc. announced a registered direct offering to sell 3,225,000 shares of common stock at $1.20 per share, anticipating gross proceeds of approximately $3.9 million.
- During July 2025, Scienture Holdings, Inc. approved a capital raise of up to $3 million by issuing shares at $1.59 each, having already received approximately $1.2 million from investors for 754,716 shares sold.
- In November 2025, stockholders approved an amendment to the 2019 Equity Incentive Plan, increasing the number of common shares available for issuance from 5,000,000 to 25,000,000.
Inbound Investments
- Institutional investors agreed to purchase 3,225,000 shares of common stock in a registered direct offering in August 2025, with expected gross proceeds of approximately $3.9 million.
- In July 2025, Scienture Holdings, Inc. received approximately $1.2 million from investors including BlueCap Ventures LLC, Jinal Sheth, Nimish Sheth, and Chintan Shah through the sale of common stock.
- An agreement in October 2025 with Arena Finance Markets and Arena Special Opportunities III led to the full repayment and conversion of outstanding secured convertible debentures into common stock.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Scienture Earnings Notes | 12/16/2025 | |
| Day 5 of Loss Streak for Scienture Stock with -70% Return (vs. -87% YTD) [10/30/2025] | 10/31/2025 | |
| How Low Can Scienture Stock Really Go? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Trade Ideas
Select ideas related to SCNX.
| Date | Ticker | Company | Category | Trade Strategy | 6M Fwd Rtn | 12M Fwd Rtn | 12M Max DD |
|---|---|---|---|---|---|---|---|
| 02272026 | BRBR | BellRing Brands | Dip Buy | DB | FCF Yield | Low D/EDip Buy with High Free Cash Flow YieldBuying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap | 0.0% | 0.0% | 0.0% |
| 02272026 | LLY | Eli Lilly | Monopoly | MY | Getting CheaperMonopoly-Like with P/S DeclineLarge cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple | 0.0% | 0.0% | 0.0% |
| 02132026 | STZ | Constellation Brands | Dip Buy | DB | FCFY OPMDip Buy with High FCF Yield and High MarginBuying dips for companies with high FCF yield and meaningfully high operating margin | 5.7% | 5.7% | 0.0% |
| 02132026 | KMB | Kimberly-Clark | Insider | Insider Buys | Low D/EStrong Insider BuyingCompanies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | 1.9% | 1.9% | -1.7% |
| 02062026 | AVO | Mission Produce | Insider | Insider Buys | Low D/EStrong Insider BuyingCompanies with strong insider buying in the last 1 month, positive operating income and reasonable debt / market cap | 1.1% | 1.1% | -2.7% |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 164.51 |
| Mkt Cap | 333.6 |
| Rev LTM | 63,795 |
| Op Inc LTM | 21,100 |
| FCF LTM | 10,718 |
| FCF 3Y Avg | 10,550 |
| CFO LTM | 16,642 |
| CFO 3Y Avg | 14,016 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 7.3% |
| Rev Chg 3Y Avg | 2.9% |
| Rev Chg Q | 9.6% |
| QoQ Delta Rev Chg LTM | 2.4% |
| Op Mgn LTM | 30.3% |
| Op Mgn 3Y Avg | 24.6% |
| QoQ Delta Op Mgn LTM | 1.3% |
| CFO/Rev LTM | 25.6% |
| CFO/Rev 3Y Avg | 23.0% |
| FCF/Rev LTM | 16.8% |
| FCF/Rev 3Y Avg | 16.6% |
Valuation
| Median | |
|---|---|
| Name | |
| Mkt Cap | 333.6 |
| P/S | 6.1 |
| P/EBIT | 16.2 |
| P/E | 20.7 |
| P/CFO | 18.7 |
| Total Yield | 5.5% |
| Dividend Yield | 2.4% |
| FCF Yield 3Y Avg | 4.8% |
| D/E | 0.2 |
| Net D/E | 0.1 |
Returns
| Median | |
|---|---|
| Name | |
| 1M Rtn | -3.1% |
| 3M Rtn | 0.7% |
| 6M Rtn | 19.7% |
| 12M Rtn | 11.3% |
| 3Y Rtn | 35.8% |
| 1M Excs Rtn | 4.0% |
| 3M Excs Rtn | 9.0% |
| 6M Excs Rtn | 24.5% |
| 12M Excs Rtn | -0.2% |
| 3Y Excs Rtn | -23.0% |
Segment Financials
Revenue by Segment| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Integra | 1 | 5 | 3 | 10 | 1 |
| Scienture | 0 | ||||
| Unallocated | 0 | 0 | 0 | 0 | |
| Superlatus | 0 | ||||
| Trxade, Inc. | 5 | 5 | 6 | 5 | |
| Community Specialty Pharmacy, LLC (CSP) | 2 | 2 | 2 | ||
| Total | 1 | 10 | 10 | 17 | 7 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Scienture | 0 | ||||
| Integra | -1 | -1 | -3 | -1 | -0 |
| Unallocated | -17 | -5 | -4 | -4 | -2 |
| Superlatus | 0 | ||||
| Trxade, Inc. | 2 | 2 | 3 | 2 | |
| Community Specialty Pharmacy, LLC (CSP) | -0 | -1 | -0 | ||
| Total | -18 | -4 | -5 | -3 | -0 |
| $ Mil | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Unallocated | 12 | 1 | 3 | 5 | 3 |
| Integra | 0 | 0 | 1 | 3 | 0 |
| Scienture | 0 | ||||
| Superlatus | 0 | ||||
| Trxade, Inc. | 2 | 2 | 2 | 2 | |
| Community Specialty Pharmacy, LLC (CSP) | -0 | -0 | 0 | ||
| Total | 13 | 4 | 6 | 10 | 6 |
Price Behavior
Price Behavior
| Market Price | $0.42 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 01/26/2009 | |
| Distance from 52W High | -84.0% | |
| 50 Days | 200 Days | |
| DMA Price | $0.50 | $0.91 |
| DMA Trend | down | down |
| Distance from DMA | -16.5% | -54.4% |
| 3M | 1YR | |
| Volatility | 79.2% | 376.3% |
| Downside Capture | 0.96 | 1.58 |
| Upside Capture | 95.97 | 46.68 |
| Correlation (SPY) | 22.2% | 7.2% |
SCNX Betas & Captures as of 2/28/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 3.86 | 3.12 | 3.26 | 4.21 | 1.88 | 1.21 |
| Up Beta | 8.55 | 6.62 | 5.78 | 2.73 | 0.33 | 0.08 |
| Down Beta | 2.56 | 3.10 | 2.86 | 2.43 | 2.18 | 1.89 |
| Up Capture | 216% | 140% | 167% | 120% | 82% | 39% |
| Bmk +ve Days | 9 | 20 | 31 | 70 | 142 | 431 |
| Stock +ve Days | 9 | 21 | 29 | 53 | 105 | 325 |
| Down Capture | 336% | 259% | 313% | 269% | 165% | 111% |
| Bmk -ve Days | 12 | 21 | 30 | 54 | 109 | 320 |
| Stock -ve Days | 12 | 19 | 30 | 68 | 140 | 411 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SCNX | |
|---|---|---|---|---|
| SCNX | -78.2% | 374.8% | 0.32 | - |
| Sector ETF (XLP) | 4.6% | 13.9% | 0.09 | -2.4% |
| Equity (SPY) | 14.5% | 18.9% | 0.59 | 7.3% |
| Gold (GLD) | 50.2% | 27.7% | 1.46 | 2.0% |
| Commodities (DBC) | 17.8% | 17.6% | 0.85 | 12.8% |
| Real Estate (VNQ) | 0.4% | 16.4% | -0.15 | 4.0% |
| Bitcoin (BTCUSD) | -23.7% | 44.2% | -0.49 | 12.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SCNX | |
|---|---|---|---|---|
| SCNX | -64.3% | 220.1% | 0.16 | - |
| Sector ETF (XLP) | 6.8% | 13.2% | 0.30 | 2.6% |
| Equity (SPY) | 11.8% | 17.0% | 0.54 | 7.9% |
| Gold (GLD) | 20.7% | 17.7% | 0.96 | 3.3% |
| Commodities (DBC) | 11.6% | 18.9% | 0.50 | 7.5% |
| Real Estate (VNQ) | 3.0% | 18.8% | 0.07 | 6.8% |
| Bitcoin (BTCUSD) | 4.0% | 56.6% | 0.29 | 6.2% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with SCNX | |
|---|---|---|---|---|
| SCNX | -31.9% | 212.4% | 0.43 | - |
| Sector ETF (XLP) | 7.3% | 14.7% | 0.37 | 3.2% |
| Equity (SPY) | 14.0% | 17.9% | 0.67 | 7.7% |
| Gold (GLD) | 13.3% | 15.8% | 0.70 | 3.4% |
| Commodities (DBC) | 8.2% | 17.6% | 0.39 | 7.4% |
| Real Estate (VNQ) | 4.7% | 20.7% | 0.19 | 6.6% |
| Bitcoin (BTCUSD) | 66.4% | 66.8% | 1.06 | 7.0% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Expand for More| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 3/27/2023 | -20.8% | -38.4% | -29.5% |
| 11/7/2022 | -6.9% | -11.5% | -47.0% |
| 7/25/2022 | -6.9% | -10.3% | -24.1% |
| 3/28/2022 | 12.0% | -5.6% | -24.8% |
| 10/25/2021 | -0.7% | 1.2% | -18.9% |
| 7/26/2021 | -10.8% | -1.3% | -6.8% |
| 3/29/2021 | -27.1% | -28.5% | -38.7% |
| 10/26/2020 | -18.5% | -33.9% | -21.6% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 2 | 1 | 1 |
| # Negative | 7 | 8 | 8 |
| Median Positive | 7.6% | 1.2% | 16.4% |
| Median Negative | -10.8% | -10.9% | -24.5% |
| Max Positive | 12.0% | 1.2% | 16.4% |
| Max Negative | -27.1% | -38.4% | -47.0% |
SEC Filings
Expand for More| Report Date | Filing Date | Filing |
|---|---|---|
| 09/30/2025 | 11/12/2025 | 10-Q |
| 06/30/2025 | 08/12/2025 | 10-Q |
| 03/31/2025 | 05/12/2025 | 10-Q |
| 12/31/2024 | 03/26/2025 | 10-K |
| 09/30/2024 | 11/06/2024 | 10-Q |
| 06/30/2024 | 08/09/2024 | 10-Q |
| 03/31/2024 | 06/26/2024 | 10-Q |
| 12/31/2023 | 04/22/2024 | 10-K |
| 09/30/2023 | 01/16/2024 | 10-Q |
| 06/30/2023 | 08/18/2023 | 10-Q |
| 03/31/2023 | 05/15/2023 | 10-Q |
| 12/31/2022 | 03/27/2023 | 10-K |
| 09/30/2022 | 11/07/2022 | 10-Q |
| 06/30/2022 | 07/25/2022 | 10-Q |
| 03/31/2022 | 05/09/2022 | 10-Q |
| 12/31/2021 | 03/28/2022 | 10-K |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.